Provided by Tiger Trade Technology Pte. Ltd.

Context Therapeutics Inc.

0.4354
-0.0300-6.45%
Post-market: 0.4264-0.0090-2.06%19:56 EDT
Volume:8.17M
Turnover:3.38M
Market Cap:40.00M
PE:-0.90
High:0.4748
Open:0.4700
Low:0.3969
Close:0.4654
52wk High:3.62
52wk Low:0.3969
Shares:91.88M
Float Shares:63.73M
Volume Ratio:3.13
T/O Rate:12.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4828
EPS(LYR):-0.3800
ROE:-76.14%
ROA:-45.70%
PB:1.05
PE(LYR):-1.15

Loading ...

Context downgraded to Market Perform from Outperform at LifeSci Capital

TIPRANKS
·
Aug 07

Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 06

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move

Benzinga Earnings
·
Aug 06

Context Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Context Therapeutics Q2 FY26 Net Loss Widens 65% to $14.56 Million Year over Year

Reuters
·
Aug 06

Context Therapeutics Inc. Q2 Net Income USD -14.6 Million

THOMSON REUTERS
·
Aug 06

Context Therapeutics Inc. Q2 Basic EPS USD -0.15

THOMSON REUTERS
·
Aug 06

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

THOMSON REUTERS
·
Aug 06

Context Therapeutics Receives Nasdaq Minimum Bid Price Notice

TIPRANKS
·
Aug 01

Context Therapeutics Gets NASDAQ Notice for Failing $1 Minimum Bid Price Rule

Reuters
·
Aug 01

Context Therapeutics Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview

Reuters
·
Aug 01

Context Therapeutics Grants New Hire Stock Options for 146,000 Shares at $0.7 Each

Reuters
·
Jul 11

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 11

Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst

TIPRANKS
·
Jul 10

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

THOMSON REUTERS
·
Jul 07

Context Therapeutics Shareholders Approve Increase in Authorized Common Shares to 300 Million

Reuters
·
Jun 27

Context Therapeutics selloff brings buying opportunity, says JonesResearch

TIPRANKS
·
Jun 16

Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI) and Context Therapeutics (CNTX)

TIPRANKS
·
Jun 16

Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright

TIPRANKS
·
Jun 16

Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data

TIPRANKS
·
Jun 15